What: Fast-growing generic drug manufacturer Mayne Pharma Group Ltd (ASX: MYX) has announced an agreement to acquire a portfolio of 37 US Food and Drug Administration (FDA) approved and 5 FDA filed products from Teva Pharmaceutical Industries in a US$652 million deal.
So What: The pricing of the acquisition represents a multiple of under six times the projected earnings before interest, tax, depreciation and amortisation (EBITDA).
